ES2731729T3 - Uso de palmitoiletanolamida en combinación con opioides - Google Patents

Uso de palmitoiletanolamida en combinación con opioides Download PDF

Info

Publication number
ES2731729T3
ES2731729T3 ES15166284T ES15166284T ES2731729T3 ES 2731729 T3 ES2731729 T3 ES 2731729T3 ES 15166284 T ES15166284 T ES 15166284T ES 15166284 T ES15166284 T ES 15166284T ES 2731729 T3 ES2731729 T3 ES 2731729T3
Authority
ES
Spain
Prior art keywords
palmitoylethanolamide
opioid
pea
treatment
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15166284T
Other languages
English (en)
Spanish (es)
Inventor
Valle Francesco Della
Valle Maria Federica Della
Cesare Manelli Lorenzo Di
Carla Ghelardini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epitech Group SpA
Original Assignee
Epitech Group SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epitech Group SpA filed Critical Epitech Group SpA
Application granted granted Critical
Publication of ES2731729T3 publication Critical patent/ES2731729T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dispersion Chemistry (AREA)
ES15166284T 2014-05-14 2015-05-04 Uso de palmitoiletanolamida en combinación con opioides Active ES2731729T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI20140876 2014-05-14

Publications (1)

Publication Number Publication Date
ES2731729T3 true ES2731729T3 (es) 2019-11-18

Family

ID=51179022

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15166284T Active ES2731729T3 (es) 2014-05-14 2015-05-04 Uso de palmitoiletanolamida en combinación con opioides

Country Status (17)

Country Link
US (1) US9801836B2 (enExample)
EP (1) EP2944309B1 (enExample)
JP (1) JP6563685B2 (enExample)
KR (1) KR102507891B1 (enExample)
CN (1) CN105079811B (enExample)
AR (1) AR100444A1 (enExample)
AU (1) AU2015202575B9 (enExample)
BR (1) BR102015011079A2 (enExample)
CA (1) CA2891049C (enExample)
CY (1) CY1121773T1 (enExample)
DK (1) DK2944309T3 (enExample)
ES (1) ES2731729T3 (enExample)
HU (1) HUE044915T2 (enExample)
PL (1) PL2944309T3 (enExample)
PT (1) PT2944309T (enExample)
SM (1) SMT201900345T1 (enExample)
TR (1) TR201908936T4 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7244992B2 (ja) * 2015-05-21 2023-03-23 エスシーアイ スパーク リミティド オピオイドとｎ－アシルエタノールアミンの組み合わせ
SG10201802129QA (en) 2017-07-05 2019-02-27 Frimline Private Ltd A pharmaceutical composition for neuropathic pain
PH12018000227B1 (en) 2017-09-05 2019-03-11 Frimline Private Ltd A pharmaceutical composition for improving or preventing progression of chronic kidney disease
WO2020141546A1 (en) * 2019-01-02 2020-07-09 Celagenex Research (India) Pvt. Ltd. Synergistic nutritional compositions for pain management
EP4681710A1 (en) * 2024-07-18 2026-01-21 EPITECH GROUP S.p.A. 2-pentadecyl-2-oxazoline as an opioid adjuvant to prevent or treat hyperalgesia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1271266B (it) 1994-12-14 1997-05-27 Valle Francesco Della Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi
WO2001010434A1 (en) 1999-08-06 2001-02-15 Innovet Italia S.R.L. Pharmaceutical compositions containing n-palmitoylethanolamide and use thereof in the veterinary field
DE60228713D1 (de) 2001-07-18 2008-10-16 Unilever Nv Zusammensetzungen für die behandlung von haaren und/oder kopfhaut
US20050245557A1 (en) * 2003-10-15 2005-11-03 Pain Therapeutics, Inc. Methods and materials useful for the treatment of arthritic conditions, inflammation associated with a chronic condition or chronic pain
CA2756178A1 (en) * 2009-03-27 2010-09-30 Abbott Laboratories Compounds as cannabinoid receptor ligands
ES2548190T3 (es) * 2009-09-07 2015-10-14 Epitech Group S.P.A. Composición que contiene palmitoiletanolamida ultramicronizada

Also Published As

Publication number Publication date
BR102015011079A2 (pt) 2016-03-29
SMT201900345T1 (it) 2019-07-11
KR20150130931A (ko) 2015-11-24
JP6563685B2 (ja) 2019-08-21
PT2944309T (pt) 2019-06-05
HUE044915T2 (hu) 2019-11-28
AR100444A1 (es) 2016-10-05
JP2015221794A (ja) 2015-12-10
EP2944309A1 (en) 2015-11-18
KR102507891B1 (ko) 2023-03-08
US9801836B2 (en) 2017-10-31
CN105079811B (zh) 2020-06-23
AU2015202575A1 (en) 2015-12-03
AU2015202575B2 (en) 2020-03-05
CA2891049A1 (en) 2015-11-14
US20150328173A1 (en) 2015-11-19
CA2891049C (en) 2023-02-21
CY1121773T1 (el) 2020-07-31
CN105079811A (zh) 2015-11-25
TR201908936T4 (tr) 2019-07-22
DK2944309T3 (da) 2019-06-03
AU2015202575B9 (en) 2020-03-26
PL2944309T3 (pl) 2019-09-30
EP2944309B1 (en) 2019-03-20

Similar Documents

Publication Publication Date Title
JP6495191B2 (ja) 鎮痛薬の組合せおよびその使用
JP6216305B2 (ja) 薬物過量摂取の治療のためのモルヒナン誘導体
CZ20023214A3 (cs) Farmaceutická kompozice pro léčení akutní, chronické a/nebo neuropatické bolesti a migrén
JP2025092508A (ja) デクスメデトミジン製剤を使用する睡眠障害の予防または治療
ES2748274T3 (es) Remedio para aliviar los problemas de la piel que comprende un derivado de morfinano o una sal de adición de ácido farmacológicamente aceptable del mismo como el principio activo
JP2000508341A (ja) 片頭痛の治療法及び薬効の強化組成物
EP2944309B1 (en) Use of palmitoylethanolamide in combination with opioids
CZ20012084A3 (cs) Pouľití apomorfinu při výrobě léku pro léčbu organické erektilní dysfunkce u muľů
EP1154795B1 (en) Means for treating and diagnosing restless legs syndrome
CN105828821A (zh) 具有κ活性的阿片受体拮抗剂和沃替西汀用于治疗具有忧郁特征的抑郁障碍的用途
JP2008110970A (ja) アゼラスチンと抗コリン薬を含有する医薬組成物
ES2980120T3 (es) Formas de dosificación y usos terapéuticos de la L-4-cloroquinurenina
JP2009539942A (ja) ビフェプルノックス及びｌ−ｄｏｐａを含む組み合わせ製剤
JP2014505113A (ja) 末梢作用性μオピオイドアンタゴニスト
MX2012005538A (es) Combinacion de farmacos con teobromina y su uso en terapia.
KR20090125748A (ko) 대상포진 후 신경통 치료용 정제 및 대상포진 후 신경통의 치료 방법
US20010034320A1 (en) NK1-receptor antagonists for treating restless legs syndrome
WO2016018178A1 (ru) Комплексное антиникотиновое средство
WO2007148950A1 (es) Composición farmacéutica sinergística de ketorolaco y clonixinato de lisina
TW202440096A (zh) 雌激素受體降解劑之給藥方案
EP3590511A1 (en) Therapeutic agent for alcohol use disorders
ITMI20090174A1 (it) Uso di memantina per il trattamento di disturbi dell umore
MX2008002189A (en) Synergistic pharmaceutical composition of ketorolac and lysine clonixinate
WO2008075997A1 (en) Method for treating opioid withdrawal syndrome